Allarity Therapeutics, Inc. (ALLR): Nasdaq/NYSE listing notice — Allarity receives Nasdaq additional delisting basis for bid price non-compliance; panel to decide

Allarity Therapeutics, Inc.

Received Nasdaq letter on May 23, 2023 confirming failure to regain $1.00 minimum bid price by May 22, 2023 deadline.
Bid price non-compliance will serve as an additional basis for delisting, considered by Hearings Panel.
Panel heard Company's appeal on May 18, 2023 regarding stockholders' equity requirement non-compliance.
Company will provide additional information to Panel by required timeframe to support continued listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

May 23, 2023, the Company received a letter from the Nasdaq Regulation staff (“Letter”) stating that the Company did not regain compliance under the Rule by May 22, 2023, and such non-compliance will serve as an additional basis for delisting of the Company’s common stock from The Nasdaq Stock Market. Further, the Nasdaq Hearings Panel, which on May 18, 2023, heard the Company’s appeal for non-compliance with the stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5450(b)(1)(A), will consider the Letter in their decision regarding the Company’s continued listing on The Nasdaq

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-043580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.